BTIG Research Reaffirms “Buy” Rating for Serina Therapeutics (NYSEAMERICAN:SER)

Serina Therapeutics (NYSEAMERICAN:SER)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research note issued on Monday, Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research‘s price target indicates a potential upside of 367.84% from the stock’s previous close.

Serina Therapeutics Trading Up 3.6%

NYSEAMERICAN SER traded up $0.06 during trading on Monday, hitting $1.71. The stock had a trading volume of 38,290 shares, compared to its average volume of 1,431,775. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. The stock has a market capitalization of $43.43 million, a price-to-earnings ratio of -0.90 and a beta of 1.19. Serina Therapeutics has a one year low of $1.22 and a one year high of $5.25. The stock has a 50 day simple moving average of $2.24 and a 200 day simple moving average of $2.08.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

About Serina Therapeutics

Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability.

Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.